SUNSHINE BIOPHARMA INC.
SUNSHINE BIOPHARMA INC. (SBFM): 50 pipeline candidates · 9 upcoming catalysts · ~18 mo cash runway · 36 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.8 months
D/E 0.30 · 0% dilution
Lead: Approved
50 candidates
9 upcoming, next in ~196d
N/A
A transparent, data-derived signal for SUNSHINE BIOPHARMA INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.6M
Cash
$6.9M
Quarterly Burn
$2.1M
Runway
17.8 mo
Revenue
$8.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (50 candidates)
| Drug | Phase |
|---|---|
| amlodipine | Approved |
| apixaban | Approved |
| ara-c±ida | Phase 3 |
| aripiprazole | Approved |
| azithromycin | Approved |
| brivaracetam | Approved |
| clarithromycin | Approved |
| clifutinib | Phase 3 |
| ct053ptsa | Phase 2 |
| degludec insulin | Phase 3 |
Showing 10 of 50 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$124K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 46,248 | $48K |
| two sigma securities, llc | 23,482 | $24K |
| xtx topco ltd | 21,457 | $22K |
| morgan stanley | 14,634 | $15K |
| commonwealth equity services, llc | 13,437 | $14K |
| national bank of canada /fi/ | 9 | $9 |
| osaic holdings, inc. | 2 | $2 |
| corecap advisors, llc | 1 | $1 |
| farther finance advisors, llc | 1 | $1 |
| td waterhouse canada inc. | 1 | $1 |
Frequently asked questions
How many drug candidates are in SUNSHINE BIOPHARMA INC.'s pipeline?
SUNSHINE BIOPHARMA INC. (SBFM) has 50 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SUNSHINE BIOPHARMA INC.'s lead drug candidate?
SUNSHINE BIOPHARMA INC.'s most advanced tracked candidate is amlodipine (Approved).
What is SUNSHINE BIOPHARMA INC.'s next catalyst?
SUNSHINE BIOPHARMA INC.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: The Drug-Drug Interaction Study of Clifutinib" — expected December 31, 2026.
What is SUNSHINE BIOPHARMA INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SUNSHINE BIOPHARMA INC. has approximately 17.8 months of cash runway.
What is SUNSHINE BIOPHARMA INC.'s market capitalization?
SUNSHINE BIOPHARMA INC.'s market capitalization is approximately $3.6M.
Get the full picture on SUNSHINE BIOPHARMA INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.